Ayala Pharmaceuticals Forward P/E
What is the Forward P/E of Ayala Pharmaceuticals?
The Forward P/E of Ayala Pharmaceuticals Inc. is -0.14
What is the definition of Forward P/E?
Forward price to earnings ratio is the ratio of a company’s stock price to the company’s estimated earnings per share for the next twelve months.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Forward P/E of companies in the Health Care sector on NASDAQ compared to Ayala Pharmaceuticals
What does Ayala Pharmaceuticals do?
advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Companies with forward p/e similar to Ayala Pharmaceuticals
- Frequency Therapeutics Inc has Forward P/E of -0.18
- Titan Medical has Forward P/E of -0.17
- Tenax Therapeutics Inc has Forward P/E of -0.16
- Corbus Pharmaceuticals Inc has Forward P/E of -0.15
- BioXcel Therapeutics Inc has Forward P/E of -0.15
- Ontrak Inc has Forward P/E of -0.14
- Ayala Pharmaceuticals has Forward P/E of -0.14
- Digital Ally has Forward P/E of -0.13
- Lannett Co has Forward P/E of -0.11
- EVIO has Forward P/E of -0.11
- Arcadia Biosciences Inc has Forward P/E of -0.11
- Reliance Communications has Forward P/E of -0.10
- Rubius Therapeutics Inc has Forward P/E of -0.09